3-deazaneplanocin has been researched along with Bile Duct Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, H; Beppu, T; Hashimoto, D; Hayashi, H; Kuroki, H; Mima, K; Nakagawa, S; Okabe, H; Sakamoto, K; Sakamoto, Y; Tokunaga, R; Yokoyama, N | 1 |
1 other study(ies) available for 3-deazaneplanocin and Bile Duct Cancer
| Article | Year |
|---|---|
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Polycomb Repressive Complex 2; RNA Interference; RNA, Small Interfering | 2014 |